Interventional Pain Management Valuation: 2026

This report was compiled from M&A transaction records, proprietary valuation databases, and publicly available sector research to provide physician-owners with a current, data-supported analysis of interventional pain management (IPM) valuations as of 2026. The methodology triangulates reported transaction multiples across practice profiles with observable market trends, regulatory developments, and structural demand indicators.

Key Findings:

• The U.S. pain management market is projected to grow from $44.5B in 2024 to $53.6B by 2030, driven by a chronic pain prevalence rate of 24.3% among U.S. adults
• IPM practices generally transact between 4x and 11x+ EBITDA in 2026, with ASC ownership likely increasing multiples above comparable office-only practices
• Beyond scale, procedural diversification (SCS, RFA, intrathecal pumps) is the clearest separator between mid-range and premium valuations
• More than 15 PE-backed platforms are active in the IPM space, with deal volume peaking at 15 transactions in both 2022 and 2023 before moderating into a quality-selective buyer environment
• The NO PAIN Act, CMS reimbursement extensions through 2027, and updated CDC clinical guidelines are directly expanding the reimbursable procedure set for IPM providers

2026 Interventional Pain Management Valuation Multiples by Practice Profile

The table below reflects directional EV/EBITDA multiple ranges observed across U.S. interventional pain management transactions, organized by practice profile and EBITDA tier. These ranges are based on transactions reported through PitchBook, Capital IQ, and advisory firm databases compiled through mid-2026, and they encompass both platform formation and add-on acquisition activity.¹·⁵

Source: CT Acquisitions, internal guidance.

*Intended for education purposes and not a guarantee of any outcome. Each transaction is unique.

Three key findings emerge from this data:

1. ASC ownership is the primary multiple-builder in interventional pain. Practices with ambulatory surgery center ownership can transact at higher multiples than comparable office-only practices within the same EBITDA tier. The ASC represents both a higher-margin procedural venue, a means of revenue diversification, and a strategic growth asset for platform acquirers.⁷·⁸ ASCs can also contribute to physician alignment depending on the deal structure used.
2. Procedural complexity commands a meaningful premium over injection-only operations. Practices performing spinal cord stimulator (SCS) implants, intrathecal pump placements, radiofrequency ablation (RFA), kyphoplasty, and transforaminal epidurals can achieve substantially higher buyer interest than those limited to facet injections and medication management.⁸
3. Premium multiples are reserved for platform-ready assets. The 9x–11x+ range reflects multi-state footprints with in-network commercial contracts, institutional management infrastructure, meaningful ASC ownership, and stable operations with a strong balance sheet.⁶

Valuation Multiples by EBITDA Scale

Practice scale has a direct and measurable impact on valuation in the interventional pain management sector. The table below illustrates the relationship between adjusted EBITDA size and typical multiple ranges, derived from reported transactions and advisory benchmarks.⁷·⁸

Source: works cited combined with guidance from internal bankers, based generally on knowledge and experience. Actual pricing varies with each transaction based on many factors. Intended for educational purposes only and not a guarantee of any outcome.

Scale can compress buyer-perceived risk while expanding the pool of institutional acquirers eligible to underwrite a transaction.

The range differential from the same underlying profitability illustrates why pre-sale positioning and process structure can carry significant financial consequences for practice owners. Practices below $3M in EBITDA typically attract PE-backed platform add-on buyers, while those above $5M can attract both new platform sponsors and strategic consolidators.⁵·⁶

Key Valuation Drivers and Their Effect on Multiples

The following table summarizes the most consistently cited premium and compression factors across IPM transactions, based on buyer underwriting criteria and reported deal dynamics from PitchBook, advisory research, and healthcare M&A databases.

Source: works cited combined with guidance from internal bankers, based generally on knowledge and experience. Actual pricing varies with each transaction based on many factors. Intended for educational purposes only and not a guarantee of any outcome.

The valuation hierarchy is consistent across buyer types: ASC ownership combined with a diversified procedural mix, larger roster and footprint, and a clean opioid compliance record represents the ideal IPM asset. A practice meeting all three criteria may trade well above a comparable-EBITDA injection-only practice with Medicare concentration and single-physician dependency, an outcome that reflects buyer risk-weighting as much as revenue quality.⁶·⁸

Pain Management M&A Transaction Volume (2021–2025)

Deal volume in the interventional pain management sector has grown from a thin pre-consolidation baseline, driven by the formation of new PE platforms and the accelerating add-on cadence of existing operators. More than 15 traditional PE-backed pain management platforms are currently active in the U.S. market, a figure that reflects both legacy operator growth and new entrants.⁶

Source: Capital IQ, PitchBook, and press releases, as compiled by KPMG Corporate Finance LLC (October 2025).¹·⁵ Intended for educational purposes only.

Geographic concentration has emerged as a defining characteristic of the IPM M&A market. Of all transactions tracked since 2021, the South leads with 34 reported deals, followed by the West with 15 and the Midwest with 6. The Northeast accounts for 4 transactions over the same period.¹ Texas has emerged as the most active single state for IPM platform concentration, with nine PE-backed platforms operating in the state as of mid-2024, driven by its favorable regulatory environment, large insured population, and substantial supply of independent pain practices.⁶

Pain Management Market Size and Demand Fundamentals

Interventional pain management operates against a backdrop of structural, demographic-driven demand that has insulated the sector from broader macroeconomic cyclicality. The table below presents key market and demand metrics underpinning the investment thesis for pain management platform formation and add-on consolidation.

Source: IBISWorld (December 2024); KPMG Corporate Finance LLC (October 2025); CDC (November 2024); Medscape (May 2025); Hyde Park Capital / Mordor Intelligence (2024). Intended for educational purposes only.

Three regulatory developments are actively reinforcing the demand and reimbursement outlook for IPM services through at least 2027:

1. NO PAIN Act (effective 2025): Expands Medicare reimbursement to make separate payment for qualified non-opioid treatments — specifically drugs, biologics, and devices — in hospital outpatient department and ASC settings, directly enlarging the reimbursable procedure set and EBITDA profile for IPM practices that have shifted away from pharmacological-only management.¹
2. CDC First-Line Treatment Guidance: The CDC’s updated clinical practice guidelines formally recommend non-opioid and non-pharmacologic therapies as first-line treatment for chronic pain, accelerating patient and payer demand for the interventional procedures that drive premium valuations in this sector.³

Connect with the FOCUS Healthcare Team

FOCUS Investment Banking specializes in maximizing transaction value for medical practice owners through our proven quarterback approach to M&A advisory. If you would like to learn more about our healthcare investment banking services or discuss how current market conditions affect the value of your practice, you can reach out to Eric Yetter or Andy Snyder.

Sources

1. KPMG Corporate Finance LLC. Pain Management Services M&A. October 2025. corporatefinance.kpmg.us.
2. IBISWorld. Pain Management Physicians in the US. December 2024. ibisworld.com.
3. Centers for Disease Control and Prevention. Chronic Pain and High-impact Chronic Pain in U.S. Adults. November 2024. cdc.gov.
4. Medscape. A Nation in Pain. May 2025. medscape.com.
5. Capital IQ and PitchBook. Pain management M&A transaction records, 2021–2025. As compiled by KPMG Corporate Finance LLC, October 2025.
6. Physician Growth Partners. State of Pain Management Private Equity. Summer 2024. physiciangrowthpartners.com.
7. SovDoc. How to Value a Pain Management Practice: A 2025 Guide. June 2025. sovdoc.com.
8. CT Acquisitions. Selling a Pain Management Practice: Multiples, Named Buyers, and the Operator Playbook. 2026. ctacquisitions.com.
9. Hyde Park Capital Advisors. Interventional Pain Management Market Insights. Spring 2024. hydeparkcapital.com.
10. VMG Health. 2026 Healthcare M&A Report. 2026. vmghealth.com.
11. Office of National Statistics. Multimodal Interprofessional Pain Management Offers Relief With Less Opioids. February 2025.